Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253523 | 1.00 | IDO1 (0.48) | IDO1SSTR4ARCYP4F2CYP4A11 | |
| SCHEMBL3250749 | 0.81 | LMNA (0.52) | CYP4F2CYP4A11VCPIRAK4 | |
| SCHEMBL3250752 | 0.81 | LMNA (0.52) | CYP4F2CYP4A11VCPIRAK4 | |
| SCHEMBL3254209 | 0.81 | SLC22A12 (0.45) | ARCYP4F2CYP4A11IRAK4 | |
| SCHEMBL3254205 | 0.81 | SLC22A12 (0.45) | ARCYP4F2CYP4A11IRAK4 | |
| SCHEMBL4658854 | 0.79 | SSTR4 (0.43) | IDO1SSTR4ARIRAK4 | |
| SCHEMBL12359254 | 0.78 | IDO1 (0.46) | IDO1SSTR4ARIRAK4 | |
| SCHEMBL3269883 | 0.76 | ABCB1 (0.60) | — | |
| SCHEMBL3269886 | 0.76 | ABCB1 (0.60) | — | |
| SCHEMBL30438176 | 0.76 | ALOX15 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001478-B1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-02 | — | — | EP | claimed |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-23 | — | — | US | claimed |
| EP-2001478-B1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | CBR3, RXFP4, ODC1 | IDO1 1020/4885SSTR4 187/4885AR 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.